-
Mashup Score: 1
ASCO 2023 PRESTO, PSA nadir and its association with subsequent PSA progression-free survival, patients with high-risk biochemically relapsed prostate cancer, ADT + apalutamide, ADT + apalutamide + abiraterone acetate plus prednisone.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
ASCO GU 2023 results of a secondary analysis of the PRESTO trial, high-risk biochemically relapsed prostate cancer, apalutamide +/- abiraterone/prednisone, Gleason Score ≥ 9 prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Baseline characteristics associated with PSA PFS in pts with high-risk biochemically relapsed #ProstateCancer: results from the phase 3 #PRESTO study (AFT-19). Presented by Rahul Aggarwal, MD @UCSFCancer. @ASCO #GU23 written coverage by @rksayyid @UofT > https://t.co/tbEX1Aho1w https://t.co/yB1IGQG1GT
-
-
Mashup Score: 1
In this brief commentary, Charles Ryan highlights the phase 3, open-label PRESTO study, its importance, and its uniqueness being the first phase 3 study in serologic relapse prostate cancer with a positive result. Many of these patients with serologic relapse are destined to experience metastatic disease, castration-resistant prostate cancer, and death from the disease. The PRESTO study or the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19) - Rahul Aggarwal - 1 year(s) ago
In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer. PRESTO is looking at a finite duration of treatment for patients with a rising PSA after prior surgery in the biochemically recurrent, hormone-sensitive setting. There were three treatment arms. The standard of care was ADT monotherapy, the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
In this brief commentary, Charles Ryan highlights the phase 3, open-label PRESTO study, its importance, and its uniqueness being the first phase 3 study in serologic relapse prostate cancer with a positive result. Many of these patients with serologic relapse are destined to experience metastatic disease, castration-resistant prostate cancer, and death from the disease. The PRESTO study or the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19) - Rahul Aggarwal - 1 year(s) ago
In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer. PRESTO is looking at a finite duration of treatment for patients with a rising PSA after prior surgery in the biochemically recurrent, hormone-sensitive setting. There were three treatment arms. The standard of care was ADT monotherapy, the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19) - Rahul Aggarwal - 1 year(s) ago
In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer. PRESTO is looking at a finite duration of treatment for patients with a rising PSA after prior surgery in the biochemically recurrent, hormone-sensitive setting. There were three treatment arms. The standard of care was ADT monotherapy, the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
In this brief commentary, Charles Ryan highlights the phase 3, open-label PRESTO study, its importance, and its uniqueness being the first phase 3 study in serologic relapse prostate cancer with a positive result. Many of these patients with serologic relapse are destined to experience metastatic disease, castration-resistant prostate cancer, and death from the disease. The PRESTO study or the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 6Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19) - Rahul Aggarwal - 1 year(s) ago
In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer. PRESTO is looking at a finite duration of treatment for patients with a rising PSA after prior surgery in the biochemically recurrent, hormone-sensitive setting. There were three treatment arms. The standard of care was ADT monotherapy, the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
In this brief commentary, Charles Ryan highlights the phase 3, open-label PRESTO study, its importance, and its uniqueness being the first phase 3 study in serologic relapse prostate cancer with a positive result. Many of these patients with serologic relapse are destined to experience metastatic disease, castration-resistant prostate cancer, and death from the disease. The PRESTO study or the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
Depth of PSA nadir and subsequent PSA PFS in patients with high-risk biochemically relapsed #ProstateCancer: results from the phase 3 #PRESTO study (AFT-19). Presented by Rahul Aggarwal, MD @UCSF. #ASCO23 written coverage by @RKSayyid @UofT > https://t.co/fG9iQ4mI5T @ASCO https://t.co/lMtelEb3Gr